Compare MIRM & GFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | GFF |
|---|---|---|
| Founded | 2018 | 1959 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2019 | N/A |
| Metric | MIRM | GFF |
|---|---|---|
| Price | $64.32 | $76.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $87.55 | ★ $95.75 |
| AVG Volume (30 Days) | ★ 616.7K | 360.4K |
| Earning Date | 11-04-2025 | 11-19-2025 |
| Dividend Yield | N/A | ★ 1.14% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.09 |
| Revenue | $471,794,000.00 | ★ $2,519,926,000.00 |
| Revenue This Year | $53.78 | $1.35 |
| Revenue Next Year | $19.91 | $3.17 |
| P/E Ratio | ★ N/A | $70.64 |
| Revenue Growth | ★ 53.66 | N/A |
| 52 Week Low | $36.88 | $63.92 |
| 52 Week High | $78.55 | $84.24 |
| Indicator | MIRM | GFF |
|---|---|---|
| Relative Strength Index (RSI) | 35.49 | 61.17 |
| Support Level | $63.66 | $72.67 |
| Resistance Level | $66.77 | $74.27 |
| Average True Range (ATR) | 2.99 | 1.99 |
| MACD | -0.69 | 0.54 |
| Stochastic Oscillator | 9.63 | 85.92 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.